Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Phase 1

Recruiting

• Conditions: Cholangiocarcinoma; Endometrial Cancer; Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Sarcoma; Other Solid Tumours
• Interventions: Drug: CPL304110

• Registration Number: NCT04149691
• Lead Sponsor: Celon Pharma SA

Brief Summary

The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.

Detailed Description

01FGFR2018 is an Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects with Advanced Solid Malignancies. The study consists of 3 parts: initial dose escalation (Part 1 - without FGFR, fibroblast growth factor receptor, molecular aberrations), dose escalation (Part 2 - with FGFR molecular aberrations) and dose extension (Part 3 - with FGFR molecular aberrations).

Study Timeline

• Study Start: 2019-07-19
• Study First Submitted: 2019-10-31
• Study First Submitted QC: 2019-10-31
• Study First Posted: 2019-11-04
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-06
• Last Update Posted: 2024-02-07
• Primary Completion: 2024-06
• Study Completion: 2024-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol related
• age of ≥25 years old
• Performance Score ≥70 in accordance with the Karnofsky Performance Score (KPS),
• life expectancy period of at least 3 months on the screening day,
• Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
• subject (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception
• adequate blood, liver, renal and urine parameters
• phosphate levels within normal range
• HIV, HCV (hepatitis C virus) and HBV negative (hepatitis B virus),
• adequate cardiac function

Inclusion Criteria Specific for parts:

Part 1

• Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, cholangiocarcinoma, sarcoma or endometrial cancer, be refractory to prior therapies and without effective further treatment options.

Part 2 and 3

• Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, be refractory to prior therapies and without effective further treatment options.
• Subject's archival formalin-fixed paraffin-embedded (FFPE) tumour sample available for molecular alteration diagnostics, and/or a possibility to collect a new biopsy.
• Present molecular alteration within FGFR 1, 2 or 3

Read More

Exclusion Criteria

• Any other current malignancy or malignancy diagnosed within the past five (5) years.
• Active brain metastases or leptomeningeal metastases.
• concurrent anticancer treatment within 28 days before the start of trial treatment; major surgery within 28 days before the start of trial treatment); use of blood transfusion within 7 days before the start of trial treatment,
• prior therapy with an agent directed to another FGFR inhibitor,
• pregnancy and/or breastfeeding,
• phosphate levels above the upper limit of normal,
• ectopic calcification/mineralization,
• endocrine alteration related to calcium/phosphate homeostasis e.g. parathyroid disorders, history of parathyroidectomy,
• concomitant therapies increasing calcium/phosphate serum levels,
• inability to take oral medicines,
• corneal disorder and/or keratopathy,
• persisting toxicity related to prior therapy Grade > 1 CTCAE v5.0, except polyneuropathy and alopecia,
• clinically significant (i.e., active) cardiovascular disease. History of abdominal fistula, bowel obstruction (Grade IV), gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment. Other significant diseases, which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment.
• Receipt of any organ transplantation including allogeneic stem-cell transplantation.

Exclusion Criteria Specific for parts:

Part 2 and 3

• No FFPE tumour sample available to conduct FGFR alteration eligibility tests and no biopsy option.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CPL304110	CPL304110	CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD)	First cycle of 28 days	Maximum tolerated dose (MTD) of CPL304110 when administered orally once daily to adults with advanced solid malignancies. The MTD is the highest dose associated with the occurrence of dose-limiting toxicities (DLTs) in \<33% of patients.
Safety profile	First cycle of 28 days	Overall safety profile of CPL304110, as assessed by the type, frequency, severity, timing, and relationship to study drug of any adverse events (AEs), serious adverse events (SAEs), and changes in vital signs, ECGs, and safety laboratory test.

Secondary Outcome Measures

Name	Time	Method
ORR, objective rate response	Approximately up to 12 months	ORR, objective rate response defined as the rate of confirmed complete response (CR) or partial response (PR) by RECIST 1.1.
Area under the plasma concentration versus time curve AUC from 0 to infinity (AUC0-inf)	up to 24 hours after CPL304110 administration	AUC0-inf defines the area under the curve of plasma concentration vs time, from time point zero extrapolated to infinity
Time to maximum plasma concentration (tmax)	up to 24 hours after CPL304110 administration	tmax defines Time to reach maximum plasma concentration
Kel: Terminal elimination rate constant	up to 24 hours after CPL304110 administration	Terminal elimination rate constant
Area under the plasma concentration versus time curve (AUC) from 0 up to the time of last quantifiable concentration (AUC0-t)	up to the time of last quantifiable concentration after CPL304110 administration	AUC(0-t) defines the area under the curve of plasma concentration vs time, from time point zero up to the time of last quantifiable concentration
Maximum plasma concentration (Cmax)	up to 24 hours after CPL304110 administration	Cmax defines the maximum concentration of the product in plasma during observation period.
Recommended Phase 2 Dose (RP2D) determined on the base of the MTD.	Approximately up to 12 months	The RP2D will be determined after review and discussion of the pharmacokinetics (PK) profile, type and severity of drug related toxicity and clinical suitability for long-term administration.
Terminal half-life (t½)	up to 24 hours after CPL304110 administration	Plasma elimination half-life

Trial Locations

Locations (7)

BioResearch Group sp. z o.o.; 🇵🇱 Nadarzyn, Poland

Klinika Onkologii, Europejskie Centrum Zdrowia; 🇵🇱 Otwock, Poland

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie; 🇵🇱 Warsaw, Poland

Instytut Gruźlicy i Chorób Płuc; 🇵🇱 Warsaw, Poland

SP ZOZ MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie; 🇵🇱 Olsztyn, Poland

Uniwersyteckie Centrum Kliniczne w Gdańsku; 🇵🇱 Gdańsk, Poland

Wojskowy Instytut Medyczny; 🇵🇱 Warsaw, Poland